TORRAY INVESTMENT PARTNERS LLC: ROYALTY PHARMA PLC (RPRX): Quarterly 13F Position History
As of Q2 2026, TORRAY INVESTMENT PARTNERS LLC reported 602,028 shares of ROYALTY PHARMA PLC (RPRX), worth $33.8M and representing 4.6% of its 13F equity book. Quarter-over-quarter share count change: 43,397 (-6.7%) . The position first appeared in Q4 2021 and has been disclosed across 19 13F-HR filings in Pactolio's tracked window.
- 602,028Shares Held (Latest Filing)
- $33.8MReported Market Value (Latest Filing)
- 4.6%Portfolio Weight (% of 13F Equity Book)
- 43,397Quarter-over-Quarter Share Change
- +$2.8MQuarter-over-Quarter Value Change
- 862,018Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 19 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 602,028 | 43,397 | -6.7% | $33.8M | 4.6% | $56.1 |
| Q1 2026 | 645,425 | 98,930 | -13.3% | $31.0M | 4.5% | $48.0 |
| Q4 2025 | 744,355 | +41,472 | +5.9% | $28.8M | 4.1% | $38.6 |
| Q3 2025 | 702,883 | +14,107 | +2.0% | $24.8M | 3.4% | $35.3 |
| Q2 2025 | 688,776 | 173,242 | -20.1% | $24.8M | 3.6% | $36.0 |
| Q1 2025 | 862,018 | +178,011 | +26.0% | $26.8M | 4.0% | $31.1 |
| Q4 2024 | 684,007 | 173,912 | -20.3% | $17.4M | 2.5% | $25.5 |
| Q3 2024 | 857,919 | +164,361 | +23.7% | $24.3M | 3.4% | $28.3 |
| Q2 2024 | 693,558 | +686,181 | +9301.6% | $18.3M | 2.7% | $26.4 |
| Q1 2024 | 7,377 | 498,363 | -98.5% | $20.3M | 3.0% | $2758.5 |
| Q4 2023 | 505,740 | +93,107 | +22.6% | $14.2M | 2.3% | $28.1 |
| Q3 2023 | 412,633 | 1,182 | -0.3% | $11.2M | 2.0% | $27.1 |
| Q2 2023 | 413,815 | +276,643 | +201.7% | $12.7M | 2.2% | $30.7 |
| Q1 2023 | 137,172 | 199 | -0.1% | $4.9M | 0.9% | $36.0 |
| Q4 2022 | 137,371 | 1,653 | -1.2% | $5.4M | 1.0% | $39.5 |
| Q3 2022 | 139,024 | +12 | +0.0% | $5.6M | 1.1% | $40.2 |
| Q2 2022 | 139,012 | +6,942 | +5.3% | $5.8M | 1.1% | $42.0 |
| Q1 2022 | 132,070 | 5,871 | -4.3% | $5.1M | 0.8% | $39.0 |
| Q4 2021 | 137,941 | — | — | $5.5M | 0.8% | $39.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did TORRAY INVESTMENT PARTNERS LLC first disclose a RPRX position in 13F-HR filings?
TORRAY INVESTMENT PARTNERS LLC first reported ROYALTY PHARMA PLC (RPRX) on its 13F-HR filing for the period ending 2021-12-31 (Q4 2021). The position has appeared on 19 reported quarters within Pactolio's tracked window.
What was TORRAY INVESTMENT PARTNERS LLC's most recent quarter-over-quarter share-count change in RPRX?
Between Q1 2026 and Q2 2026, TORRAY INVESTMENT PARTNERS LLC reduced its RPRX position by 43,397 shares (-6.7%), leaving 602,028 shares at a market value of $33.8M.
Does the implied price-per-share represent TORRAY INVESTMENT PARTNERS LLC's cost basis in RPRX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.